Potential Advantages
There are significant limitations to the current therapies for treating a range of tissue and organ abnormalities, and there is a clear need for approaches that are safer, more effective and cost-efficient.
Tengion's technology has the potential to offer several major advantages over current best practice. Tengion neo-organs and tissues have the potential, once approved and commercially available, to:
- Provide an unlimited supply of certain organs
- Regenerate native function and structure
- Avoid the risk of organ rejection
- Eliminate the burden and costs of immunosuppression
- Reduce or eliminate other adverse effects of existing procedures
- Provide meaningful clinical safety and efficacy advances versus existing alternatives
- Shorten surgical and recovery time
- Potentially reduce healthcare costs for organ failure while improving medical outcomes
- Improve quality of life for patients and their families
The Company’s IND to study the Tengion Neo-Bladder in patients was accepted by the FDA in 2006, and we have initiated three Phase II clinical trials at multiple medical centers in the U.S.
More information on Phase II clinical trials is available at www.clinicaltrials.gov.
- For more information on the study of the Tengion Neo-Bladder Augment for the treatment of neurogenic bladder in spina bifida, click here.
- For more information on the study of the Tengion Neo-Bladder Augment for the treatment of neurogenic bladder following spinal cord injury, click here.
- For more information on the study of the Tengion Neo-Bladder Augment for the treatment of urge incontinence, click here.